CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
Vitamin Ddrug
Likely dose
Vitamin D 6000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00656019
NCT00656019Phase 2Completed

Development of Vitamin D as a Therapy for Breast Cancer - Phase 2

Stanford University·interventional·Posted Apr 10, 2008·Updated Dec 2, 2017

In Brief

A Phase 2 clinical trial evaluating Vitamin D for Breast Cancer. Completed, enrolled 63 participants across 1 site.

Detailed Summary

This study will assess whether levels of vitamin D impact the characteristics of a woman's breast cancer at diagnosis, and whether a short course of vitamin D in women with low levels of vitamin D changes the gene expression of their breast cancers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 10, 2008
Enrollment StartApr 1, 2008
Primary CompletionAug 1, 2010
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.2 years ago

Interventions

Vitamin Ddrug

0, 2000, 4000, and 6000 IU per day orally